albuterol has been researched along with Idiopathic Parkinson Disease in 6 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Excerpt | Relevance | Reference |
---|---|---|
"The albuterol-treated patients demonstrated reduced parkinsonian symptoms and an increased ability to tap their index finger between two points 20 cm apart, and were able to perform a "walk test" in 70% of their control time." | 2.67 | Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease. ( Alexander, GM; Grothusen, JR; Hooker, MD; Nukes, TA; Schwartzman, RJ, 1994) |
" Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract." | 1.51 | Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. ( Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Gillette, C | 1 |
Cooney, JW | 1 |
Sisson, CB | 1 |
Rockich-Winston, N | 1 |
Perry, CJ | 1 |
Moore, WC | 1 |
Mittal, S | 1 |
Bjørnevik, K | 1 |
Im, DS | 1 |
Flierl, A | 1 |
Dong, X | 1 |
Locascio, JJ | 1 |
Abo, KM | 1 |
Long, E | 1 |
Jin, M | 1 |
Xu, B | 1 |
Xiang, YK | 1 |
Rochet, JC | 1 |
Engeland, A | 1 |
Rizzu, P | 1 |
Heutink, P | 1 |
Bartels, T | 1 |
Selkoe, DJ | 1 |
Caldarone, BJ | 1 |
Glicksman, MA | 1 |
Khurana, V | 1 |
Schüle, B | 1 |
Park, DS | 1 |
Riise, T | 1 |
Scherzer, CR | 1 |
Fletcher, EJR | 1 |
Jamieson, AD | 1 |
Williams, G | 1 |
Doherty, P | 1 |
Duty, S | 1 |
Alexander, GM | 1 |
Schwartzman, RJ | 1 |
Nukes, TA | 1 |
Grothusen, JR | 1 |
Hooker, MD | 1 |
Martin, S | 1 |
Hishida, R | 1 |
Kurahashi, K | 1 |
Narita, S | 1 |
Baba, T | 1 |
Matsunaga, M | 1 |
1 trial available for albuterol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.
Topics: Aged; Albuterol; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
5 other studies available for albuterol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Levodopa inhalation powder in a patient with persistent asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dopamine Agents; Dry Powder In | 2020 |
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.
Topics: Acetylation; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; alpha-Synu | 2017 |
Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.
Topics: Albuterol; Animals; Brain; Computer Simulation; Corpus Striatum; Dimethadione; Dopaminergic Neurons; | 2019 |
Pharmaceutical review: salbutamol - madopar - isocal.
Topics: Albuterol; Australia; Benserazide; Humans; Hydrazines; Levodopa; Lung Diseases; Parenteral Nutrition | 1978 |
"Wearing-off" and beta 2-adrenoceptor agonist in Parkinson's disease.
Topics: Aged; Albuterol; Brain; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Di | 1992 |